In T2DM patients who had already treated with OHAs, fasting IRI and/or HOMA-IR index could not necessarily be markers of insulin resistance, thus further supporting the clinical relevance of measuring baseline serum levels of PEDF in identifying T2DM patients who may benefit most from additional OHAs therapy. Here, SERPINF1 is linked to type 2 diabetes mellitus.